FDA Approves Edwards Lifesciences Autus Valve as First-Ever Expandable Pediatric Heart Valve
The FDA has approved the Edwards Lifesciences Autus valve, marking it as the first expandable pediatric heart valve designed to grow with children. This breakthrough addresses the critical need for an alternative to static cardiac implants, which often require multiple invasive surgeries for children with congenital heart defects. The Autus valve uses synthetic polymer leaflets to resist calcification and can be expanded non-surgically via transcatheter balloon dilation, significantly reducing the physical and emotional burden on young patients and their families.
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Edwards Lifesciences (NYSE: EW) announced it will host an investor event on Monday, November 2, from 5:00 to 6:00 PM Pacific Time, coinciding with the TCT annual scientific symposium in San Diego. The event will feature a live Q&A session with physicians and Edwards' management team, and a live webcast will be available on the company's investor relations website. An archived version of the webcast will be accessible later the same day.
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve
Edwards Lifesciences has received FDA approval for its AUTUS Size-Adjustable Valve, the first expandable pediatric heart valve designed for children with congenital heart disease. This innovative device expands with the child's growth, potentially reducing the need for multiple open-heart surgeries, and features synthetic polymeric leaflets. Clinical trials showed a 100% success rate with no major complications, marking a significant advancement in pediatric cardiac care.
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Edwards Lifesciences has received FDA approval for its AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric patients with congenital heart disease. This valve can be expanded through a minimally invasive transcatheter procedure as a child grows, potentially reducing the need for multiple open-heart surgeries. The approval is based on positive clinical trial results showing excellent safety and effectiveness, and it represents a significant advancement in treatment options for pediatric congenital heart patients.
Edwards Lifesciences wins FDA approval for AUTUS
Edwards Lifesciences has received FDA approval for its AUTUS pediatric pulmonary valve, designed for children with congenital pulmonary valve disease. This innovative valve can be surgically implanted and later expanded via a catheter as the child grows, potentially reducing the need for multiple surgeries. The FDA's approval was based on a 62-child study, noting the valve's early performance but also flagging longer-term risks.
Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adj
Edwards Lifesciences (EW) has received FDA clearance for its AUTUS Size-Adjustable Valve, a surgical pulmonary valve for pediatric patients with congenital heart disease, addressing the need for fewer repeated open-heart surgeries as children grow. Despite insider selling, the company is considered approximately 9.5% undervalued with a strong GF Score of 95/100, reflecting robust fundamentals, profitability, growth, and momentum. This innovation positions Edwards Lifesciences at the forefront of pediatric cardiovascular care technology and offers a compelling growth story with a fair valuation.
Edwards Lifesciences Says US FDA Approves AUTUS Pediatric Pulmonary Valve
Edwards Lifesciences announced that the US Food and Drug Administration (FDA) has approved its AUTUS pediatric pulmonary valve. This news was released by MT Newswires, indicating a significant development for the company in the medical device sector. The full article content requires a premium subscription.
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Edwards Lifesciences has received FDA approval for its AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric patients with congenital heart disease. This innovative valve can be expanded as a child grows, potentially reducing the need for multiple open-heart surgeries through minimally invasive transcatheter procedures. The approval is based on a pivotal study demonstrating the valve's safety and effectiveness, addressing a significant unmet need for children requiring pulmonary valve replacement.
US wireless carriers name Paul Roth interim CEO for satellite connectivity venture
AT&T, T-Mobile, and Verizon have appointed Paul Roth as interim CEO for their new joint venture focused on expanding satellite-enabled mobile coverage. The initiative aims to eliminate dead zones, provide redundant connectivity during disasters, and improve network performance through "direct to device" satellite technology. This venture comes amidst competition from Elon Musk's SpaceX, which plans to develop a full-fledged mobile service using Starlink satellites.
ADSEW - ADS-TEC ENERGY PLC Warrant stock news, filings & ratings
This article provides an overview of ADS-TEC ENERGY PLC Warrant (ADSEW), a B2B technology company specializing in intelligent battery buffered energy systems. It details the company's products, stock performance, recent SEC filings, and relevant news, highlighting its market position within the Industrial Specialties industry.
GE HealthCare hires new global chief AI officer
GE HealthCare has appointed Rodolphe Katra, former global chief AI officer at Medtronic, as its new global chief AI officer. Katra will report to CTO Taha Kass-Hout and focus on integrating devices, software, and data to enhance AI strategies. This appointment follows the departure of GE HealthCare's first chief AI officer, Parminder Bhatia, and aims to further cement the company's leadership in AI-enabled medical devices, of which it currently has 134 FDA-authorized.
Why Are Traders Reassessing Edwards Lifesciences (NYSE:EW)?
Edwards Lifesciences (NYSE:EW) is gaining attention as healthcare companies face scrutiny regarding product adoption, clinical evidence, and procedure demand in a defensive market. The key question for the company is whether its structural-heart technologies can sustain consistent execution. Investors should monitor company disclosures for evidence on demand, delivery, capital allocation, and priorities related to these technologies to determine if the current interest reflects genuine operational progress.
US28176EAD0 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Edwards Lifesciences Corporation bond US28176EAD0, highlighting its key facts, coupon payments, and redemption information. It covers issuer details, maturity date, face value, and the semi-annual fixed rate coupon of 4.30%, along with a schedule of upcoming and past payouts. The bond, issued by a medical innovations company, matures on June 15, 2028.
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27
Edwards Lifesciences (NYSE:EW) has received a "Moderate Buy" rating from analysts, with an average target price of $100.27, suggesting an upside from its current share price of $86.39. The company recently surpassed quarterly earnings and revenue expectations and has significant institutional ownership. Despite some insider selling, analysts maintain a positive outlook, with several firms reiterating "buy" or "outperform" ratings and increasing price targets.
Zimmer Biomet stock trades at USD 91.57, up 2.10 percent in New York trading
Zimmer Biomet stock traded at USD 91.57, up 2.10 percent in New York trading, outperforming the SPY's 0.46 percent gain. The stock opened at USD 89.53 and reached a session high of USD 91.84, with trading volume at 474,121 shares. Analyst estimates from Zacks support the move, with 10 analysts revising fiscal 2026 earnings estimates higher and the company also announced a quarterly dividend of USD 0.24 per share with a record date of September 30, 2026.
Claim your share of the $39 million Edwards Lifesciences securities class action settlement
Investors who purchased Edwards Lifesciences Corp. common stock between February 6, 2024, and July 24, 2024, may be eligible to claim a portion of a $39 million class action settlement. The lawsuit alleged that Edwards Lifesciences and its CEO made misleading statements about the growth prospects of the company's transcatheter aortic valve replacement platform. The deadline to file a claim online or via mail is December 2, 2026.
Medtronic plc (MDT) Options Chain - Yahoo Finance
This article provides the options chain data for Medtronic plc (MDT) from Yahoo Finance. It indicates that as of the reporting time, there are no calls or puts listed for MDT. The article also notes MDT's current stock price, recent dividend announcement, and links to related tickers.
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action - EW
Rosen Law Firm is reminding investors who purchased Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024, and July 24, 2024, about the December 13, 2024 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Edwards Lifesciences made misleading statements regarding its 2024 revenue projections, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) product. Investors are encouraged to contact Rosen Law Firm to join the class action.
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW
Andra AP fonden has significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 49.0% in the second quarter, now owning 171,269 shares valued at $15.49 million. Other institutional investors have also adjusted their holdings in the medical research company. Edwards Lifesciences reported strong Q2 earnings, beating analyst estimates, and has received a "Moderate Buy" consensus rating from analysts with an average target price of $100.27.
DexCom, Inc. (DXCM) stock price, news, quote and history
This page provides comprehensive financial information for DexCom, Inc. (DXCM), including its current stock price, historical data, and key financial metrics. It details the company's market performance, valuation measures, profitability, and allows for comparison with similar companies in the industry. The article also provides the stock's performance during regular and overnight trading sessions.
AtriCure (ATRC) Stock Looks Pricey Against Its Sales Base
AtriCure (ATRC) stock has seen a significant 59.5% return over the past year, but its current P/S ratio of 5.2x is considerably higher than the Medical Equipment industry average of 2.9x, suggesting it may be overvalued relative to its sales base. While some analysts see potential for growth driven by new clinical adoptions, others express caution due to competitive risks from new market entrants. Investors should evaluate whether the company's commercial execution can justify this premium.
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Orchestra BioMed announced that its investigational Atrioventricular Interval Modulation (AVIM) Therapy will be highlighted in two sessions at HRX Live 2026. The sessions will cover the collaboration with Medtronic for AVIM Therapy's development to treat hypertensive heart disease in pacemaker-indicated patients and discuss its expanding role beyond traditional bradycardia pacing. This reflects growing recognition of AVIM Therapy's potential to address uncontrolled hypertension, a significant global health concern.
J&J sells Laminar LAA closure assets it bought 3 years ago
Johnson & Johnson is selling the assets of Laminar, a company it acquired in November 2023 for its left atrial appendage closure device, after suspending a pivotal trial due to safety concerns. The assets are being bought by Jaguar LAA, a newly formed company backed by Santé Ventures, which plans to continue developing the technology. J&J's decision is part of its strategy to focus resources on high-growth areas within its medtech portfolio.
LMRI - Lumexa Imaging Holdings Inc Volatility & Greeks
This article provides a detailed financial overview of Lumexa Imaging Holdings Inc (LMRI), including its latest stock price, market capitalization, key financial ratios, earnings per share, and institutional/insider ownership. It also presents volatility metrics, price performance over various periods, and analyst recommendations. The data highlights various financial health indicators and market sentiment for the company.
Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW
Bank of America Corp DE has acquired a significant new stake in Edwards Lifesciences Corporation (NYSE:EW), purchasing over 6.69 million shares valued at approximately $605.40 million during the second quarter. This move makes Bank of America Corp DE a 1.16% owner of Edwards Lifesciences. Other institutional investors have also adjusted their holdings, while several analysts have issued "buy" or "outperform" ratings for the stock with price targets around $100-$110.
Edwards Lifesciences, Medtronic score CMS win for TAVR
Edwards Lifesciences and Medtronic, leading medtech companies, have received positive news from CMS regarding expanded Medicare coverage for Transcatheter Aortic Valve Replacement (TAVR). CMS's finalized national coverage decision will now include patients with asymptomatic severe aortic stenosis and removes the evidence development requirement for symptomatic cases. This move is expected to streamline patient care, increase TAVR procedure volumes, and reinforces the value of multidisciplinary heart teams.
Stock Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW)
Edwards Lifesciences (NYSE: EW) experienced a significant surge in options trading activity, with traders purchasing 2,518 call options, a 93% increase over the average daily volume. The company recently exceeded quarterly earnings expectations, reporting $0.78 EPS and $1.74 billion in revenue, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $100.27. Despite some insider selling, institutional investors have substantially increased their holdings in the medical technology firm.
Edwards Lifesciences Insider Daniel Lippis Sells 619 Shares at $87.51 Following Option Exercise
Edwards Lifesciences executive Daniel Lippis exercised options for 619 shares at $72.68 each and subsequently sold them for $87.51 per share on September 11, 2026. Following this transaction, Lippis retained 40,034 shares and 3,714 derivative securities. The exercised options represented approximately 14.3% of his previous derivative securities holdings, while the shares sold were about 1.5% of his total shareholding before the sale.
Corient Private Wealth LP Acquires 227,947 Shares of Edwards Lifesciences Corporation $EW
Corient Private Wealth LP significantly increased its stake in Edwards Lifesciences Corporation by over 1,000%, acquiring an additional 227,947 shares. This move is part of a broader trend of institutional investors, including California State Teachers Retirement System and BlackRock Inc., increasing their holdings in the medical research company. The article also details recent analyst ratings, insider trading activity, and positive news regarding CMS expanding TAVR coverage, which is expected to boost demand for Edwards Lifesciences' products.
California State Teachers Retirement System Purchases 26,490,456 Shares of Zimmer Biomet Holdings, Inc. $ZBH
The California State Teachers Retirement System significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7,899.1% in the second quarter, acquiring an additional 26,490,456 shares. This makes the fund a major holder with 26,825,816 shares valued at $2.31 billion, representing 14.06% of the company. Other institutional investors also adjusted their positions, while an insider sold a portion of their holdings.
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C
Insider Daniel Lippis recently sold 619 shares of Edwards Lifesciences Corp (EW), part of a consistent pattern where he has sold 10,230 shares over the past year with no purchases. This insider selling trend is reinforced by the broader company data showing 40 insider sells and 0 insider buys in the last year, suggesting a negative insider sentiment despite the stock being "Modestly Undervalued" according to GuruFocus's GF Value. Investors are advised to consider this insider activity alongside valuation and guru ownership data, which shows a mixed institutional interest.
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock By Investing.com
Daniel J. Lippis, CVP at Edwards Lifesciences Corp, sold 619 shares of company stock for $54,168 on September 11, 2026, at $87.51 per share. Concurrently, he acquired 619 shares through employee stock options at an exercise price of $72.68. This transaction was conducted under a Rule 10b5-1 trading plan adopted in February 2026.
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock
Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, sold 619 shares of company stock worth $54,168 at $87.51 per share on September 11, 2026. Concurrently, he acquired 619 shares through employee stock options at an exercise price of $72.68 per share. These transactions, conducted under a Rule 10b5-1 trading plan, leave Mr. Lippis with over 40,000 shares, and occurred while the stock was trading below the sale price, though InvestingPro analysis suggests fair valuation.
Edwards Lifesciences stock price target maintained at $85 by Canaccord
Canaccord maintained a Hold rating and an $85.00 price target on Edwards Lifesciences following a Medicare coverage decision for transcatheter aortic valve replacement (TAVR) procedures. The Centers for Medicare & Medicaid Services (CMS) formalized Medicare coverage for asymptomatic severe aortic stenosis and removed facility-level procedural volume thresholds, which is expected to drive longer-term volume growth. Despite this positive development, Canaccord notes that the implementation and adoption of the new National Coverage Determination (NCD) will take time, influencing their cautious rating.
Edwards Lifesciences stock price target maintained at $85 by Canaccord
Canaccord has reiterated a Hold rating and an $85 price target for Edwards Lifesciences (NYSE:EW) after Medicare finalized coverage for transcatheter aortic valve replacement (TAVR) procedures, including those for asymptomatic severe aortic stenosis. Despite the stock trading above Canaccord's target at $86.77 and a premium valuation, 15 analysts have revised earnings downwards for the upcoming period, adding a cautious note to the Hold rating. The finalized Medicare policy is expected to be a long-term tailwind for TAVR due to formalized coverage, removal of facility volume thresholds, and increased workflow flexibility.
TriCo Bancshares (NASDAQ:TCBK): What Comes Next?
TriCo Bancshares (NASDAQ:TCBK) is gaining market attention due to stronger-than-expected quarterly earnings, despite a cautious outlook from analysts. The company, which operates through Tri Counties Bank, shows resilience in community banking, consistent dividend distribution, and significant institutional ownership. The article explores how TriCo's strong operational performance and unique position in community banking might influence its market narrative and valuation in the evolving financial landscape.
Edwards Lifesciences Corporation $EW Stock Holdings Lifted by California State Teachers Retirement System
California State Teachers Retirement System significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 9,187.8% during the second quarter, now holding over 80 million shares valued at $7.32 billion. Other institutional investors also acquired substantial new stakes in the medical research company. Edwards Lifesciences reported strong Q2 earnings, beating analyst estimates, and has received "Buy" ratings from several Wall Street analysts with an average target price of $100.27.
25,021 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Jupiter Topco LLC
Jupiter Topco LLC recently acquired 25,021 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $2.16 million, according to its latest 13F filing. Other institutional investors have also adjusted their holdings in the medical equipment provider. Analysts have issued varied ratings for ZBH, with a consensus "Hold" and an average target price of $104.42, while the company recently reported strong quarterly earnings and declared a quarterly dividend.
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day
Edwards Lifesciences Corp. (EW) stock fell 1.15% on Thursday, closing at $89.78, despite a strong day for the broader market with the S&P 500 and Dow Jones Industrial Average both rising over 1%. The company's shares are currently 6.76% below their 52-week high of $96.29, achieved on July 7th.
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit 2026
Edwards Lifesciences (NYSE: EW) announced it will participate in the Deutsche Bank Healthcare Summit on Wednesday, September 16, 2026. Bernard Zovighian, CEO, and Doretta Mistras, CFO, will represent the company, with Zovighian scheduled to present at 10:00 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH
UBS AM, a unit of UBS Asset Management Americas LLC, reduced its stake in Zimmer Biomet Holdings, Inc. by 0.9% in the second quarter, selling 12,667 shares but retaining 1.46 million shares valued at approximately $125.5 million. The medical equipment provider exceeded quarterly earnings expectations, reporting an adjusted EPS of $2.07 and revenue of $2.18 billion, with a year-over-year revenue increase of 4.8%. Analysts maintain a consensus "Hold" rating for ZBH, with an average price target of $104.42.
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical (ISRG) is prioritizing aggressive investment in research and development (R&D) to ensure long-term growth, despite current macroeconomic challenges and competitive pressures. This strategy focuses on innovation, including AI/ML and robotics, to expand into new disease areas like GI, cardiac, and lung interventions, rather than short-term cost-cutting. The company believes this will broaden its addressable market and strengthen its competitive moat, similar to peers like Edwards Lifesciences and Glaukos who also maintain substantial R&D spending.
Edwards Lifesciences (EW) SVP, Corporate Controller Andrew Dahl Sells 544 Shares
Edwards Lifesciences' SVP, Corporate Controller Andrew Dahl sold 544 shares of the company's stock on August 31, 2026. This transaction is part of a broader trend of insider selling at the company, with 39 insider sells and no buys over the past year. The stock is currently deemed "Fairly Valued" by GuruFocus, and the insider selling, combined with mixed guru activity, suggests a cautious sentiment among sophisticated investors despite the company's strong market position.
NS Partners Ltd Reduces Stake in Edwards Lifesciences Corporation $EW
NS Partners Ltd significantly reduced its stake in Edwards Lifesciences Corporation by 32.3% in the second quarter, selling over 62,000 shares. Despite this, the company reported strong quarterly earnings, exceeding analyst expectations with $0.78 EPS and a 13.6% revenue increase year-over-year. Analyst sentiment for Edwards Lifesciences remains positive, with a consensus "Moderate Buy" rating and an average price target of $100.27, although company insiders have recently sold shares.
Van ECK Associates Corp Decreases Holdings in Edwards Lifesciences Corporation $EW
Van ECK Associates Corp reduced its stake in Edwards Lifesciences Corporation by 9.8% in Q2 2026, selling 13,722 shares but still retaining over $11.4 million worth of stock. Despite this, institutional investors hold a significant 79.46% of the company's shares. Edwards Lifesciences reported strong Q2 earnings, beating estimates with $0.78 EPS and a 13.6% revenue increase to $1.74 billion, leading analysts to maintain a "Moderate Buy" rating with an average price target of $100.27.
Edwards Lifesciences (NYSE: EW) officer files to sell $238K in shares
An officer at Edwards Lifesciences (NYSE: EW), Annette Bruls, has filed a Form 144 to sell 2,644 shares of common stock, valued at approximately $237,907. These shares were primarily acquired through restricted stock lapses from equity compensation awards. The filing indicates a neutral impact and sentiment regarding the potential sale.
Edwards Lifesciences SVP sells $49,533 in stock By Investing.com
Andrew M. Dahl, SVP, Corporate Controller at Edwards Lifesciences Corp (NASDAQ:EW), sold 544 shares of company stock for a total of $49,533 on August 31, 2026, at a price of $91.055 per share. This transaction leaves Mr. Dahl with 14,868.41 shares. The sale occurred while the stock was near its 52-week high, and InvestingPro data suggests the shares are slightly overvalued.
Edwards Lifesciences SVP Andrew M. Dahl Sells 544 Shares Under Employee Stock Purchase Plan
Andrew M. Dahl, Senior Vice President and Corporate Controller at Edwards Lifesciences Corp, sold 544 shares of common stock at $91.055 per share on August 31, 2026, under the company's Employee Stock Purchase Plan. Following this transaction, Dahl directly owns 14,868.41 shares of Edwards Lifesciences. This transaction was disclosed via an SEC Form 4 and reflects routine quarterly share acquisitions.
Edwards Lifesciences (NYSE:EW) SVP Sells 544 Shares of Stock
Andrew Dahl, SVP of Edwards Lifesciences (NYSE:EW), sold 544 shares of the company's stock for approximately $49,537, reducing his stake by 3.53%. This insider sale comes as Edwards Lifesciences reported strong quarterly earnings, beating EPS estimates by $0.04 and seeing revenue increase by 13.6% year-over-year. Analysts currently hold a "Moderate Buy" consensus rating for the stock, with an average price target of $100.27.
Edwards Lifesciences SVP sells $49,533 in stock
Andrew M. Dahl, SVP at Edwards Lifesciences Corp, sold 544 shares of company stock for $49,533 on August 31, 2026, at a price of $91.055 per share. Following the sale, he beneficially owns 14,868.41 shares. This transaction occurred amidst positive analyst coverage and strong Q2 results for the company.
